MUMBAI, INDIA / ACCESSWIRE / March 6, 2017 / Groupe Athena, Inc. (OTC PINK: GATA) made the following announcement:
The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.
Groupe Athena, Inc. announced today that based on current orders on hand, revenues would be in the range of $52.5 million to $55 million in the current fiscal as against the previous estimate of $50 million.
As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. The Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
News 
Market Data 
Discover 
